A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.
Prevalence of hepatitis C virus (HCV) infection has decreased in both the blood donor (BD) and haemodialysis (HD) populations but remains high in the intravenous drug user (IVDU) population, a Singapore study has found.
Patients with advanced hepatocellular carcinoma (HCC) and elevated α-fetoprotein concentration who were previously treated with sorafenib had improved overall survival (OS) and progression-free survival (PFS) following treatment with ramucirumab, according to results of the phase III REACH-2* trial.
Responders showed better overall survival (OS) than nonresponders to treatment for hepatocellular carcinoma (HCC), according to an exploratory analysis of the REFLECT trial, suggesting that objective response (OR) is an independent predictor of OS in these patients.
Patients with chronic hepatitis C virus (HCV) infection who are treated with direct-acting antivirals (DAAs) have a reduced risk of all-cause mortality and hepatocellular carcinoma (HCC), according to results of an observational French study.
Achieving sustained virological response in hepatitis C virus (HCV)-infected patients with type 2 diabetes (T2D) substantially cuts the risk of developing acute coronary syndrome, end‐stage renal disease, ischaemic stroke and retinopathy, regardless of cirrhosis, a study has shown.
Liraglutide was as effective as a structured supervised lifestyle modification programme combining diet and exercise for reducing weight, liver damage, and liver fat at 26 weeks in obese Asians with nonalcoholic fatty liver disease (NAFLD), a study shows.
While liraglutide successfully induces weight loss in obese adults with nonalcoholic fatty liver disease (NAFLD), its benefits were not preserved after discontinuation, unlike that of lifestyle modification, according to a new Singapore study.
A once-daily oral dose of sofosbuvir and velpatasvir for 12 weeks leads to sustained virological response (SVR) in a majority of patients with chronic hepatitis C virus (HCV) infection, according to an Asian study. However, the efficacy of this regimen may be reduced in patients with HCV genotype 3b with cirrhosis.
Patients with nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) suffer from higher surgical morbidity and posthepatectomy liver failure, according to a new Singapore study.